Garland J. Scott 4

What Happened
Garland J. Scott, a director of ALX Oncology Holdings, Inc. (ALXO), was granted a derivative award on 2026-01-20 for 40,400 shares. The Form 4 reports the acquisition price as $0.00 (transaction code A — grant/award). This was an award of an option (derivative) rather than an open-market purchase or sale, so there was no cash outlay reported.

Key Details

• Transaction date: 2026-01-20; Form filed 2026-01-21 (timely filing).
• Reported acquisition: 40,400 shares (derivative award) at $0.00.
• Footnote: The shares subject to the option vest in 12 equal monthly installments beginning February 20, 2026.
• Amount owned following the transaction: not provided in the excerpt of the filing.
• Transaction code: A (award/grant). No sale, purchase, or tax withholding noted.

Context
This is a compensation-related option grant to a director — a common form of equity-based pay. As a derivative award, it gives the holder the right to acquire shares in the future subject to vesting; it does not represent an immediate market purchase or sale and should not be read as a direct bullish/bearish trade.